Epizyme

Developing and delivering novel epigenetic therapies

Epizyme’s mission is to rewrite treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of epithelioid sarcoma (ES) and non-Hodgkin’s lymphoma.

Status
NASDAQ: EPZM
Year of Investment
2020
Strategy
Life Sciences
Location
Cambridge, Massachusetts
Website